A Phase IIa Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Multiple Doses of Inhaled RNS60 and Budesonide on the Late Phase Asthmatic Response to Allergen Challenge in Patients With Mild Asthma.
Latest Information Update: 06 Nov 2021
At a glance
- Drugs RNS 60 (Primary) ; Budesonide
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Revalesio
- 04 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2015 According to ClinicalTrials.gov record, this trial has been amended to no longer be a cross-over trial; it will be parallel (RNS60/placebo) 1 period study and no longer involves the administration of budesonide.
- 07 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.